Tag: Multiple Sclerosis
Adverse Outcomes Seen With MS Disease-Modifying Drugs in Pregnancy
Significant reductions seen in birth weight with exposure to certain DMTs, and increase seen in rate of small for gestational age
Children Have Various Symptoms Within Five Years Before MS Diagnosis
Nine ICD-10 codes were seen more often in children with multiple sclerosis versus controls without MS
COVID-19 Infection Not Linked to Changes in MS Symptom Severity
Immediate effect of COVID-19 infection on the SymptoMScreen total score was minimal
Certain Risk Factors for MS Linked to Pediatric Brain Volume
MS-polygenic risk score and household parental smoking negatively linked to total brain volume, thalamic volume
Social Determinants of Health Linked to Brain MRI Outcomes in Pediatric MS
Individual- and neighborhood-level indicators of social disadvantage linked to worse MRI outcome in pediatric-onset MS
Generic Medications Can Keep OOP Costs Down for Neurological Conditions
Increase in out-of-pocket costs seen for multiple sclerosis medications per year by average of 217 percent
Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue
Change in Modified Fatigue Impact Scale scores did not differ between the groups
Cancer Incidence Increased for People With Multiple Sclerosis
Small overall risk increase was mainly seen in women; higher risk seen for bladder, brain, cervical cancers
Aggressive, Early Disease-Modifying Therapy May Slow MS Progression
Development of paramagnetic rim lesions tied to more rapid disability progression
